Exercise Guideline Safety Concerns

Exercise Guideline Safety Concerns

UBC Vancouver

1 month
14 Views
Share
Want to watch this again later?
Sign in to add this video to a playlist. Login
0 0
Category:
Description:

Kristin Campbell of @UBCnews explains exercise guidelines for cancer survivors limitations and safety concerns.

__________

There is growing evidence that exercise is a significant part of recovery for the increasing number of cancer survivors worldwide. But how much is required, and what kind of exercise?

A recent research study, undertaken by an international group of experts led by the University of British Columbia, has led to the development of new guidelines for exercise for cancer survivors.

The revised guidelines, published today in Medicine & Science in Sports & Exercise, detail detailed' exercise treatments' to tackle common side effects associated with cancer diagnosis and treatment, such as anxiety and exhaustion.

Generally speaking, the new guidelines prescribe aerobic and strength training for survivors for about 30 minutes per session, three days a week. This is a departure from earlier recommendations, issued almost a decade ago, that urged survivors of cancer to follow the general guidelines for public health for all Americans—150 minutes of exercise a week.

“Exercise has been regarded as a safe and helpful way for cancer survivors to lessen the impact of cancer treatment on their physical and mental health, but the precise type and amount of exercise to treat the many different health outcomes related to cancer treatment hasn’t been clear,” says the paper’s lead author, Dr. Kristin Campbell, associate professor at UBC’s department of physical therapy. “In the absence of this information, cancer survivors were advised to strive toward meeting the general public health guidelines for all Americans — an amount of physical activity that may be difficult for people to achieve during or following cancer treatment.”

The new recommendations are based on a thorough review and examination of the increasing range of scientific evidence in the field. There have been more than 2,500 published randomized controlled exercise trials in cancer survivors since the first guidelines were put forward in 2010, an increase of 281 percent.

The new paper is just one of three papers published today that summarize the findings of an international roundtable investigating the role of exercise in the prevention and control of cancer. The roundtable put together a team of 40 global, multidisciplinary experts from different organizations who carried out a detailed and updated analysis of research on the beneficial effects of exercise in cancer prevention, treatment and recovery.

Read here: https://www.oncologytube.com/video/new-exercise-guidelines-for-cancer-survivors-

Up Next Autoplay
Lymphopenia: How This Affects Clinicians and Treatment Today @CleClinicNews
Lymphopenia: How This Affects Clinicians and Treatment Today @CleClinicNews
Category: Non-Hodgkin Lymphoma
4 Views
Cancer-News 2 days
HORIZON Study #ASH19 @RushMedical
HORIZON Study #ASH19 @RushMedical
Category: Multiple Myeloma
0 Views
ash 2 days
Immune Status, Inflammation Can Predict Mortality @CleClinicNews @CleClinicMD
Immune Status, Inflammation Can Predict Mortality @CleClinicNews @CleClinicMD
Category: Non-Hodgkin Lymphoma
0 Views
Cancer-News 2 days
Phase I Study of Duvelisib in CLL/SLL #ASH19 #ASH @DanaFarber
Phase I Study of Duvelisib in CLL/SLL #ASH19 #ASH @DanaFarber
Category: Chronic Lymphocytic Leukemia
12 Views
ash 2 days
MANIFEST, a Phase 2 Study of CPI-0610 @MountSinaiNYC #ASH #ASH19
MANIFEST, a Phase 2 Study of CPI-0610 @MountSinaiNYC #ASH #ASH19
Category: Other
0 Views
ash 2 days
Phase I Study Evaluating NKTR-255 in MM and NHL #ASH #ASH19 @DanaFarber
Phase I Study Evaluating NKTR-255 in MM and NHL #ASH #ASH19 @DanaFarber
Category: Multiple Myeloma
2 Views
ash 3 days
Nektar Therapeutics Announces Presentation of New Preclinical Data for its IL-15 Agonist, NKTR-255, at the American Society of  Hematology (ASH) 2019 Annual Meeting
Nektar Therapeutics Announces Presentation of New Preclinical Data for its IL-15 Agonist, NKTR-255, at the American Society of Hematology (ASH) 2019 Annual Meeting
Category: Immunotherapy
2 Views
cancernewsupdate 3 days
New PreClinical Data for its IL-15 Agonist, NKTR-255 #ASH19 #ASH
New PreClinical Data for its IL-15 Agonist, NKTR-255 #ASH19 #ASH
Category: Immunotherapy
3 Views
ash 3 days
Novartis Kisqali® data show superior overall survival compared to fulvestrant and consistent efficacy across advanced breast cancer patient subgroups in MONALEESA-3
Novartis Kisqali® data show superior overall survival compared to fulvestrant and consistent efficacy across advanced breast cancer patient subgroups in MONALEESA-3
Category: Breast Cancer
2 Views
cancernewsupdate 3 days
Venetoclax-Rituximab (VenR) in Relapsed Refractory (R/R) CLL: How This Affects Clinicians? #ASH19 #ASH
Venetoclax-Rituximab (VenR) in Relapsed Refractory (R/R) CLL: How This Affects Clinicians? #ASH19 #ASH
Category: Chronic Lymphocytic Leukemia
2 Views
ash 3 days